R&D

Addiction - a growing health and economic burden


Addictive disorders represent a rappidly growing health burden on society. In the US it is estimated that the 

abuse of tobacco, alcohol, and illicit drugs is costly to our Nation, exacting more than $740 billion annually in costs related to crime, lost work productivity and health care.


Traditional therapies to treat addictive disorders are burdened with poor compliance, lack of efficacy and/or side effects. OXonium Therapeutics is pioneering the development of a novel class of anti-addictive therapies based on antagonism of the orexin 1 (Ox1) receptor.

Ox1 Antagonism - an exciting new era in anti-addictive therapies


  • Orexin has a role in reward, feeding behaviour & anxiety, attributed to the Ox1 receptor. Receptors are found in hypothalamus, enteric nervous system and gut
  • Orexin also has a role in sleep via Ox2 receptor
  • Reward stimuli known to trigger dopamine release, orexins enhance this signalling
  • Orexigenic signalling via the Ox1 receptor has been implicated in several addictive disorders

OXonium Therapeutics is developing the best in class Ox1 antagonist with an initial focus on Binge Eating Disorder (BED)


  • Structurally distinct and differentiated from competitor molecules
  • Excellent pharmacological selectivity, good brain penetration and physicochemical properties as well as good metabolic stability
  • Reduces binge eating without affecting normal food consumption
  • Full data package available under CDA
  • 2 CoM patents filed, 1 patent granted Q1 2019
  • 2 Backup series available

Copyright @ All Rights Reserved